MYNZ vs. CNTX, GRFS, LVTX, NLSP, PHVS, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and Mainz Biomed (NASDAQ:MYNZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Mainz Biomed received 1 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 76.47% of users gave Mainz Biomed an outperform vote while only 63.16% of users gave Context Therapeutics an outperform vote.
14.0% of Context Therapeutics shares are held by institutional investors. 9.4% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -2,934.82%. Mainz Biomed's return on equity of -115.50% beat Context Therapeutics' return on equity.
Context Therapeutics has higher earnings, but lower revenue than Mainz Biomed. Context Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Context Therapeutics currently has a consensus price target of $7.50, suggesting a potential upside of 309.84%. Mainz Biomed has a consensus price target of $6.00, suggesting a potential upside of 810.47%. Given Context Therapeutics' higher possible upside, analysts plainly believe Mainz Biomed is more favorable than Context Therapeutics.
Context Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
In the previous week, Context Therapeutics had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for Context Therapeutics and 3 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.52 beat Context Therapeutics' score of 0.17 indicating that Context Therapeutics is being referred to more favorably in the media.
Summary
Context Therapeutics beats Mainz Biomed on 12 of the 17 factors compared between the two stocks.
Get Mainz Biomed News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mainz Biomed Competitors List
Related Companies and Tools
